Loading clinical trials...
Loading clinical trials...
A Multi Center, Multi National, Open Label, Extension Study to Evaluate the Long-term Efficacy and Safety of BMN 044 (PRO044) in Subjects With Duchenne Muscular Dystrophy
Conditions
Interventions
BMN 044 IV 6 mg/kg
BMN 044 IV 9 mg/kg
+1 more
Locations
5
Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
S.Anna Hospital
Ferrara, Italy
Policlinico Univsersitario Agostino Gemelli
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands
Drottning Silvias Barn- ochungdomssjukhus
Gothenburg, Sweden
Start Date
April 1, 2016
Primary Completion Date
September 1, 2016
Completion Date
September 1, 2016
Last Updated
January 26, 2018
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
BioMarin Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions